Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Clearmind Medicine Inc. Common Shares (CMND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: CMND (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.78M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -1.31 | 52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 |
52 Weeks Range 0.80 - 2.30 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.23% | Return on Equity (TTM) -139.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 168145 | Price to Sales(TTM) - |
Enterprise Value 168145 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.79 | Shares Outstanding 5379440 | Shares Floating 4864790 |
Shares Outstanding 5379440 | Shares Floating 4864790 | ||
Percent Insiders 2.8 | Percent Institutions 11.19 |
Upturn AI SWOT
Clearmind Medicine Inc. Common Shares
Company Overview
History and Background
Clearmind Medicine Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel psychedelic-derived therapeutics. Founded in 2018, the company aims to address unmet needs in the treatment of alcohol use disorder (AUD) and other mental health conditions. A significant milestone was the initiation of its Phase 2a clinical trial for its lead asset, CMND-100, for alcohol use disorder. The company's evolution is centered around leveraging the therapeutic potential of psilocybin and other compounds.
Core Business Areas
- Psychedelic-Derived Therapeutics Development: Clearmind Medicine is engaged in the research, development, and clinical testing of novel psychedelic-derived compounds and treatment protocols for various mental health disorders, with a primary focus on alcohol use disorder.
Leadership and Structure
Information on Clearmind Medicine Inc.'s specific leadership team and organizational structure is not readily available in public domain for a detailed outline. However, as a clinical-stage biotechnology company, it is expected to have a management team comprising individuals with expertise in drug development, clinical trials, scientific research, and business operations.
Top Products and Market Share
Key Offerings
- CMND-100: CMND-100 is Clearmind Medicine's lead drug candidate, a proprietary formulation of psilocybin intended for the treatment of alcohol use disorder. The company is currently conducting a Phase 2a clinical trial to evaluate its safety and efficacy. There is no publicly available market share data for CMND-100 as it is still in clinical development. Competitors in the broader alcohol use disorder treatment market include pharmaceutical companies developing traditional medications and therapy providers. In the nascent psychedelic therapeutics space, competitors include companies like Compass Pathways (CMPS), MindMed (MNMD), and ATAI Life Sciences (ATAI).
Market Dynamics
Industry Overview
The psychedelic therapeutics market is a rapidly evolving and emerging sector within the broader biotechnology and pharmaceutical industries. It focuses on the development of psychedelic compounds for the treatment of various mental health conditions, including depression, anxiety, PTSD, and addiction. This industry is characterized by significant research and development activities, increasing regulatory interest, and substantial investment potential, though it faces challenges related to regulatory hurdles and public perception.
Positioning
Clearmind Medicine Inc. is positioning itself as a clinical-stage company focused on developing novel psychedelic-based treatments for significant unmet medical needs, particularly alcohol use disorder. Its competitive advantage lies in its targeted approach to specific indications and its proprietary formulation development. However, as a clinical-stage company, it faces the inherent risks associated with drug development and competition from established and emerging players in the psychedelic space.
Total Addressable Market (TAM)
The total addressable market for mental health disorders, including alcohol use disorder, is substantial. The global mental health market is projected to reach hundreds of billions of dollars. Clearmind Medicine's focus on specific indications within this market suggests a targeted TAM. Their positioning within this TAM is as a niche developer of novel therapeutic interventions, aiming to capture a segment of patients with limited treatment options.
Upturn SWOT Analysis
Strengths
- Focus on a significant unmet medical need (alcohol use disorder)
- Clinical-stage development with ongoing trials
- Proprietary formulation of psilocybin (CMND-100)
Weaknesses
- Early-stage company with unproven commercialization
- Reliance on clinical trial success
- Limited financial resources compared to larger biotechs
- Regulatory uncertainties in the psychedelic space
Opportunities
- Growing acceptance and research into psychedelic therapies
- Potential for orphan drug designation
- Partnerships and collaborations for further development and commercialization
- Expansion into other mental health indications
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Intense competition from other psychedelic companies
- Negative public perception or stigma surrounding psychedelics
- Changes in intellectual property landscape
Competitors and Market Share
Key Competitors
- Compass Pathways plc (CMPS)
- MindMed Inc. (MNMD)
- ATAI Life Sciences N.V. (ATAI)
Competitive Landscape
Clearmind Medicine Inc. faces a competitive landscape with several other companies actively developing psychedelic therapeutics. Its advantages lie in its specific focus on alcohol use disorder and its proprietary formulation. However, competitors like Compass Pathways and MindMed have more advanced clinical programs and potentially greater funding. ATAI Life Sciences operates as a holding company with a diverse portfolio, also posing significant competition through its subsidiaries.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Clearmind Medicine Inc. would be characterized by its progression from inception to clinical development, including the establishment of its R&D pipeline and the initiation of clinical trials. This growth is measured by scientific advancements and milestones achieved in the development process.
Future Projections: Future projections for Clearmind Medicine Inc. are contingent upon the successful outcomes of its clinical trials, regulatory approvals, and eventual commercialization of its therapeutics. Analyst estimates, if available, would focus on the potential market penetration and revenue generation post-approval.
Recent Initiatives: Recent initiatives would likely include the advancement of its clinical trials for CMND-100, potential collaborations, and efforts to secure further funding to support ongoing development and expansion of its research programs.
Summary
Clearmind Medicine Inc. is a clinical-stage biotechnology company operating in the emerging psychedelic therapeutics market, focusing on alcohol use disorder. Its lead candidate, CMND-100, is in Phase 2a trials. The company's strengths lie in its targeted approach and the growing interest in psychedelic medicine. However, it faces significant risks inherent in clinical development, regulatory uncertainties, and strong competition. Future success hinges on positive trial outcomes and effective fundraising to navigate the long path to commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials (where available)
- Publicly available financial data aggregators
- Industry research reports on the psychedelic therapeutics market
Disclaimers:
This analysis is based on publicly available information as of the last update and is for informational purposes only. It does not constitute financial advice. Investing in clinical-stage biotechnology companies carries substantial risk. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearmind Medicine Inc. Common Shares
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2021-08-16 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is based in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.